Profile data is unavailable for this security.
About the company
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
- Revenue in EUR (TTM)4.93m
- Net income in EUR-95.14m
- Incorporated2002
- Employees88.00
- LocationDbv Technologies SA177-181 avenue Pierre BrossoletteMONTROUGE 92120FranceFRA
- Phone+33 155427878
- Fax+33 143261083
- Websitehttps://www.dbv-technologies.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acticor Biotech SA | 0.00 | -18.65m | 60.18m | 24.00 | -- | 128.08 | -- | -- | -1.68 | -1.68 | 0.00 | 0.0298 | 0.00 | -- | -- | 0.00 | -145.59 | -- | -297.22 | -- | -- | -- | -- | -- | -- | -9.32 | 0.9504 | -- | -- | -- | -25.94 | -- | -- | -- |
| Valbiotis SA | 4.39m | -9.14m | 61.20m | 48.00 | -- | 4.12 | -- | 13.94 | -0.8427 | -0.8427 | 0.3832 | 0.9411 | 0.1816 | 0.7079 | 1.76 | 91,479.16 | -37.81 | -36.56 | -55.22 | -50.24 | 88.93 | 49.62 | -208.22 | -812.27 | 2.79 | -39.11 | 0.3656 | -- | 163.42 | 204.47 | -41.83 | -- | -14.52 | -- |
| Maat Pharma SA | 2.23m | -19.72m | 102.45m | 50.00 | -- | 5.01 | -- | 45.99 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| AB Science SA | 777.00k | -16.89m | 104.04m | 89.00 | -- | -- | -- | 133.90 | -0.3561 | -0.3561 | 0.0164 | -0.3879 | 0.0284 | 0.394 | 2.50 | 7,471.15 | -61.64 | -70.81 | -237.22 | -316.63 | 88.16 | 91.37 | -2,173.10 | -1,225.49 | 1.41 | -- | 135.44 | -- | -40.39 | -11.24 | 5.86 | -- | 5.07 | -- |
| Eurofins-Cerep SA | 46.17m | 9.21m | 109.96m | 233.00 | 11.94 | 1.83 | 9.82 | 2.38 | 1,826.41 | 1,826.41 | 9,160.00 | 11,939.29 | 0.6814 | 1.66 | 6.04 | 220,892.00 | 13.60 | 15.19 | 16.06 | 18.94 | 85.57 | 67.30 | 19.95 | 19.72 | 5.17 | 112.42 | 0.00005 | 0.00 | 14.45 | 14.30 | 17.09 | 24.52 | -- | -- |
| DBV Technologies SA | 4.93m | -95.14m | 116.69m | 88.00 | -- | 0.754 | -- | 23.67 | -1.01 | -1.01 | 0.0523 | 1.60 | 0.0209 | -- | 0.3738 | 71,443.19 | -40.35 | -64.67 | -46.22 | -80.94 | -- | 91.59 | -1,929.97 | -1,345.10 | -- | -- | 0.0128 | -- | -15.14 | -18.45 | 2.08 | -- | -38.41 | -- |
| Adocia SA | 5.73m | -20.55m | 124.10m | 100.00 | -- | -- | -- | 21.68 | -2.36 | -2.36 | 0.6532 | -1.90 | 0.1823 | -- | 16.79 | 55,048.08 | -65.43 | -25.65 | -341.43 | -37.22 | -- | -- | -358.85 | -101.11 | 0.5924 | -2.78 | 2.81 | -- | 692.73 | -10.08 | 69.67 | -- | -40.08 | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 129.95m | 62.00 | -- | 5.61 | -- | 58.35 | -1.18 | -1.18 | 0.1166 | 1.06 | 0.0256 | -- | 3.22 | -- | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -97.81 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Transgene SA | 7.63m | -22.33m | 134.13m | 158.00 | -- | 8.57 | -- | 17.57 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Eurobio Scientific SA | 128.01m | 7.91m | 151.68m | 304.00 | 19.60 | 0.9579 | 6.23 | 1.18 | 0.7552 | 0.7552 | 11.91 | 15.45 | 0.4856 | 3.75 | 4.48 | 948,222.30 | 3.00 | 21.70 | 3.53 | 28.79 | 45.28 | 50.59 | 6.18 | 25.06 | 2.70 | 4.11 | 0.3799 | 0.00 | -17.38 | 29.03 | -58.81 | -- | -6.24 | -- |
| Genfit SA | 38.18m | -28.89m | 161.22m | 159.00 | -- | 2.37 | -- | 4.22 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Inventiva SA | 17.48m | -110.43m | 165.57m | 112.00 | -- | -- | -- | 9.47 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Aelis Farma SA | 5.55m | -5.57m | 173.68m | 22.00 | -- | 10.10 | -- | 31.28 | -0.4123 | -0.4123 | 0.4187 | 1.30 | 0.1405 | -- | 1.36 | 252,409.10 | -14.09 | -30.28 | -22.24 | -49.56 | -- | -- | -100.29 | -168.22 | 2.41 | -- | 0.1337 | -- | -58.03 | -- | -2,589.20 | -- | -- | -- |
Data as of Apr 23 2024. Currency figures normalised to Dbv Technologies SA's reporting currency: Euro EUR
28.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2022 | 23.50m | 24.37% |
| Braidwell LPas of 31 Dec 2023 | 3.30m | 3.42% |
| UBS LA MAISON de Gestionas of 30 Dec 2022 | 100.00k | 0.10% |
| La Fran�aise Asset Management SASas of 29 Dec 2023 | 55.00k | 0.06% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 24.85k | 0.03% |
| HSBC Global Asset Management (France) SAas of 29 Feb 2024 | 14.85k | 0.02% |
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 3.20k | 0.00% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 421.00 | 0.00% |
| Iris Finance SAas of 31 Dec 2018 | 0.00 | 0.00% |
| Gestys SAas of 26 Jan 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2018 - 23 Feb 2024Source: FactSet Research Systems Inc.
